drugset / Trial / NCT02340104

A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants

NCT02340104

Phase 1 Completed 8 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to compare how much baricitinib (study drug) gets into the blood stream when it is given as a single dose (in tablet form) and as an intravenous infusion (injection given directly into a vein via a small needle). Each participant in the study will make four visits to the investigator site over the course of about 6 weeks.

Timeline

Start
2015-01
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 4 mg Oral
Subject [^13C4D3^15N]-baricitinib Unknown 4 ug Intravenous

Indications

No indication recorded.